Overview
Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).
Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Blast crisis in myelogenous leukaemia
- Malignant Melanoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/12/03 | Phase 2 | Not yet recruiting | |||
2024/04/11 | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | ||
2021/09/20 | Phase 2 | UNKNOWN | PETHEMA Foundation | ||
2021/05/24 | Phase 2 | Recruiting | |||
2020/01/09 | Phase 3 | Recruiting | |||
2019/08/02 | Phase 3 | Recruiting | University Hospital Muenster | ||
2018/08/22 | Phase 3 | Recruiting | Martin Schrappe | ||
2017/07/02 | Phase 3 | Active, not recruiting | University Hospital Muenster | ||
2017/01/12 | Phase 3 | UNKNOWN | |||
2016/12/08 | Phase 1 | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Vindesine Sulfate for Injection | 国药准字H20056416 | 化学药品 | 注射剂 | 3/9/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20065331 | 化学药品 | 注射剂 | 4/28/2021 | |
| Vindesine Sulfate for Injection | 国药准字H20046420 | 化学药品 | 注射剂 | 5/22/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20033311 | 化学药品 | 注射剂 | 10/24/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20045184 | 化学药品 | 注射剂 | 8/21/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20033310 | 化学药品 | 注射剂 | 10/22/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20065332 | 化学药品 | 注射剂 | 4/28/2021 | |
| Vindesine Sulfate for Injection | 国药准字H20046421 | 化学药品 | 注射剂 | 5/22/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20045185 | 化学药品 | 注射剂 | 8/21/2020 | |
| Vindesine Sulfate for Injection | 国药准字H20044956 | 化学药品 | 注射剂 | 7/27/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| ELDISINE vindesine sulfate 5mg powder for injection vial | 60703 | Medicine | A | 8/14/1997 |
Help Us Improve
Your feedback helps us provide better drug information and insights.